INZY

Inozyme Pharma, Inc.

3.61 USD

Last updated Dec 11, 23:14 UTC

Yesterday HIGH

$3.99

Yesterday LOW

$3.8

52w HIGH

$7.33

52w LOW

$0.99

EPS

-0.29

PE

-12.45

Next Earnings

Mar 20, 2024

Overview News Government Trades

Inozyme Pharma, Inc. stock is up 24.48% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 3 December’s closed higher than November.

Inozyme Pharma, Inc. engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. Lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

inozyme.com

Benzinga Insights

Wed Jul 26, 2023

12 Health Care Stocks Moving In Wednesday's Intraday Session
Charles Gross

Wed Jul 26, 2023

Inozyme Pharma Announced Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency; Said Updated Cash Runway Expected To Fund Cash Flow Requirements Into Q1 2025

Inozyme Pharma, Inc. (NASDAQ:INZY) ("Inozyme" or the "Company"), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic
Happy Mohamed

Tue Jun 27, 2023

Inozyme Pharma Announces Dosing Of First Infant With ENPP1 Deficiency In A Phase 1b Trial Of INZ-701

Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today
richadhand@benzinga.com

Wed May 10, 2023

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.
Benzinga Insights

Tue May 9, 2023

Recap: Inozyme Pharma Q1 Earnings

Inozyme Pharma (NASDAQ:INZY) reported its Q1 earnings results on Tuesday, May 9, 2023 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Inozyme Pharma beat estimated earnings by 11.11%, reporting an EPS of $-0.4 versus an estimate of $-0.45.
Happy Mohamed

Tue May 9, 2023

CORRECTION: Inozyme Pharma Q1 EPS $(0.40) Beats $(0.45) Estimate

Inozyme Pharma (NASDAQ:INZY) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 43.66 percent increase over losses of $(0.71) per share from
Benzinga Newsdesk

Tue May 9, 2023

Inozyme Pharma Q1 EPS $(0.40) Beats $(0.45) Estimate; Cash, Cash Equivalents & Short-term Investments Of $130.9M Anticipated To Fund Cash Flow Requirements Into Q4 Of 2024

Inozyme Pharma (NASDAQ: INZY) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.45) by 11.11 percent. This is a 43.66 percent increase over losses of $(0.71) per share from the same period last year.
Benzinga Insights

Wed Apr 19, 2023

Analyst Ratings for Inozyme Pharma
richadhand@benzinga.com

Wed Apr 19, 2023

Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target

Needham analyst Joseph Stringer reiterates Inozyme Pharma (NASDAQ:INZY) with a Buy and maintains $23 price target.
Happy Mohamed

Fri Apr 14, 2023

Inozyme Pharma To Present Recently Announced Preliminary Data From Ongoing Phase 1/2 Trial In ENPP1 Deficiency At The European Calcified Tissue Society Congress

Inozyme Pharma, Inc. (NASDAQ:INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today